X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1152) 1152
Publication (157) 157
Book Review (41) 41
Newsletter (18) 18
Book Chapter (5) 5
Data Set (1) 1
Dissertation (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
bortezomib (1021) 1021
index medicus (841) 841
humans (837) 837
multiple myeloma (522) 522
oncology (496) 496
multiple myeloma - drug therapy (379) 379
hematology (372) 372
female (326) 326
male (320) 320
cancer (302) 302
aged (258) 258
middle aged (250) 250
animals (235) 235
antineoplastic agents - therapeutic use (235) 235
apoptosis (227) 227
pharmacology & pharmacy (208) 208
dexamethasone (204) 204
antineoplastic combined chemotherapy protocols - therapeutic use (200) 200
proteasome inhibitors (195) 195
treatment outcome (189) 189
care and treatment (185) 185
adult (181) 181
antineoplastic agents - pharmacology (176) 176
drug therapy (170) 170
lenalidomide (170) 170
cell line, tumor (165) 165
therapy (162) 162
chemotherapy (156) 156
research (153) 153
boronic acids - therapeutic use (145) 145
multiple-myeloma (144) 144
pyrazines - therapeutic use (143) 143
boronic acids - administration & dosage (142) 142
pyrazines - administration & dosage (140) 140
proteasome inhibitor bortezomib (139) 139
boronic acids - pharmacology (137) 137
medicine & public health (135) 135
multiple myeloma - pathology (135) 135
pharmacokinetics (133) 133
pyrazines - pharmacology (133) 133
combination (125) 125
aged, 80 and over (121) 121
proteasome inhibitor (119) 119
health aspects (116) 116
carfilzomib (113) 113
dose-response relationship, drug (112) 112
mice (112) 112
antineoplastic agents - administration & dosage (111) 111
article (109) 109
apoptosis - drug effects (106) 106
thalidomide (102) 102
thalidomide - analogs & derivatives (101) 101
analysis (100) 100
proteins (99) 99
antineoplastic agents - adverse effects (98) 98
survival (97) 97
stem-cell transplantation (96) 96
antineoplastic combined chemotherapy protocols - adverse effects (94) 94
boronic acids - adverse effects (94) 94
clinical trials (94) 94
dosage and administration (92) 92
pyrazines - adverse effects (92) 92
tumors (91) 91
open-label (89) 89
clinical trials as topic (86) 86
proteasome inhibitors - pharmacology (86) 86
nf-kappa-b (82) 82
proteasome inhibitors - therapeutic use (82) 82
recurrence (82) 82
dexamethasone - administration & dosage (80) 80
medical research (80) 80
expression (79) 79
hemic and lymphatic diseases (77) 77
patients (76) 76
peripheral neuropathy (76) 76
pharmacology/toxicology (76) 76
neoplasms - drug therapy (75) 75
proteasome endopeptidase complex - metabolism (75) 75
cytotoxicity (74) 74
antineoplastic agents - pharmacokinetics (73) 73
multiple myeloma - metabolism (71) 71
cells (70) 70
drug administration schedule (69) 69
in-vitro (69) 69
toxicity (69) 69
trial (67) 67
antineoplastic agents (66) 66
hematology, oncology and palliative medicine (66) 66
proteasome (66) 66
medicine (64) 64
transplantation (64) 64
boronic acids - pharmacokinetics (63) 63
drug resistance, neoplasm (63) 63
phase-ii (63) 63
stem cells (63) 63
thalidomide - therapeutic use (63) 63
cancer therapies (61) 61
pyrazines - pharmacokinetics (61) 61
multiple myeloma - complications (60) 60
myeloma (60) 60
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Medicinal Chemistry, ISSN 0022-2623, 2019, Volume 62, Issue 7, pp. 3254 - 3267
We previously described the discovery of GSK5852 (1), a non-nucleoside polymerase (NS5B) inhibitor of hepatitis C virus (HCV), in which an N-benzyl boronic... 
IN-VITRO | CHEMISTRY, MEDICINAL | BORTEZOMIB | HEPATITIS-C VIRUS | DISCOVERY | POLYMERASE INHIBITOR | Index Medicus
Journal Article
Clinical Pharmacokinetics, ISSN 0312-5963, 01/2018, Volume 57, Issue 1, pp. 21 - 29
Histone deacetylase (HDAC) inhibitors cause an increase in acetylation that leads to an increase in DNA transcription and accumulation of different proteins,... 
DOSE-ESCALATION | ADVANCED CANCER | ADVANCED SOLID TUMORS | REFRACTORY MULTIPLE-MYELOMA | DEACETYLASE INHIBITOR | ORAL PANOBINOSTAT | PHARMACOLOGY & PHARMACY | OPEN-LABEL | PLACEBO PLUS BORTEZOMIB | JAPANESE PATIENTS | PHASE-I
Journal Article
Clinical Pharmacokinetics, ISSN 0312-5963, 05/2018, Volume 58, Issue 2, pp. 1 - 12
Proteasome inhibitors disrupt multiple pathways in cells and the bone marrow microenvironment, resulting in apoptosis and inhibition of cell-cycle progression,... 
ADVANCED SOLID TUMORS | UBIQUITIN-MEDIATED PROTEOLYSIS | DOSE DEXAMETHASONE | PHASE-I TRIAL | PROTEASOME INHIBITOR BORTEZOMIB | POTENTIAL-DRUG INTERACTIONS | NATIONAL-CANCER-INSTITUTE | PHARMACOLOGY & PHARMACY | RELAPSED MULTIPLE-MYELOMA | WALDENSTROM MACROGLOBULINEMIA | SYSTEMIC AL AMYLOIDOSIS
Journal Article
Journal Article
Investigational New Drugs, ISSN 0167-6997, 6/2018, Volume 36, Issue 3, pp. 407 - 415
This two-part, phase I study evaluated the mass balance, excretion, pharmacokinetics (PK), and safety of ixazomib in patients with advanced solid tumors. In... 
Mass balance | Medicine & Public Health | ADME | AMS | Total radioactivity | Oncology | Pharmacology/Toxicology | Pharmacokinetics | Ixazomib | DEXAMETHASONE | SAFETY | BORTEZOMIB | RENAL IMPAIRMENT | RELAPSED/REFRACTORY MULTIPLE-MYELOMA | ONCOLOGY | DRUGS | Pharmacolcinetics | LENALIDOMIDE | PHARMACOLOGY & PHARMACY | SPECTROMETRY | BLOOD | Carbon Radioisotopes - blood | Glycine - analogs & derivatives | Glycine - therapeutic use | Humans | Middle Aged | Male | Boron Compounds - administration & dosage | Female | Feces | Carbon Radioisotopes - administration & dosage | Proteasome Inhibitors - blood | Glycine - administration & dosage | Proteasome Inhibitors - pharmacokinetics | Radioactivity | Glycine - pharmacokinetics | Urine | Glycine - blood | Administration, Oral | Carbon Radioisotopes - pharmacokinetics | Proteasome Inhibitors - administration & dosage | Boron Compounds - pharmacokinetics | Treatment Outcome | Proteasome Inhibitors - therapeutic use | Neoplasms - drug therapy | Aged | Neoplasm Staging | Neoplasms - pathology | Boron Compounds - blood | Boron Compounds - therapeutic use | Excretion | Oral administration | Mass spectroscopy | Pharmacology | Patients | Proteasome inhibitors | Studies | Metabolites | Gastrointestinal system | Solid tumors | Mass spectrometry | Carbon 14 | Drug dosages | Tumors | Phase I Studies
Journal Article
Advances in Therapy: the international journal of drug, device and diagnostic research, ISSN 0741-238X, 01/2018, Volume 35, Issue 11, pp. 1859 - 1872
Journal Article
Blood, ISSN 0006-4971, 06/2017, Volume 129, Issue 25, pp. 3294 - 3303
Journal Article
British Journal of Haematology, ISSN 0007-1048, 09/2016, Volume 174, Issue 5, pp. 748 - 759
Journal Article
Blood, ISSN 0006-4971, 03/2012, Volume 119, Issue 11, pp. 2579 - 2589
Journal Article
CLINICAL PHARMACOKINETICS, ISSN 0312-5963, 01/2020, Volume 59, Issue 1, pp. 7 - 23
Non-Hodgkin lymphoma (NHL) includes a variety of closely related malignancies that originate from lymphoid precursors. The majority of NHLs are of B-cell... 
B-CELL LYMPHOMA | ADVANCED SOLID TUMORS | ANTI-CD20 MONOCLONAL-ANTIBODY | FC-GAMMA-RIIIA | CHRONIC LYMPHOCYTIC-LEUKEMIA | PROTEASOME INHIBITOR BORTEZOMIB | NATIONAL-CANCER-INSTITUTE | TYROSINE KINASE INHIBITOR | PHASE-II | PHARMACOLOGY & PHARMACY | DRUG-INTERACTION
Journal Article
Investigational New Drugs, ISSN 0167-6997, 12/2012, Volume 30, Issue 6, pp. 2303 - 2317
Purpose Combining proteasome and histone deacetylase (HDAC) inhibition has been seen to provide synergistic anti-tumor activity, with complementary effects on... 
Marizomib | NPI-0052 | Medicine & Public Health | Lung cancer | Pancreatic cancer | Melanoma | Oncology | Pharmacology/Toxicology | Proteasome | APOPTOSIS | BORTEZOMIB | ONCOLOGY | PHARMACOLOGY & PHARMACY | CASPASE-8 | MODULATION | HDAC | Lung Neoplasms - drug therapy | Pancreatic Neoplasms - metabolism | Pyrroles - pharmacokinetics | Apoptosis - drug effects | Humans | Lung Neoplasms - metabolism | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Histone Deacetylase Inhibitors - administration & dosage | Male | Antineoplastic Agents - administration & dosage | Histone Deacetylase Inhibitors - blood | Pancreatic Neoplasms - drug therapy | Histone Deacetylase Inhibitors - pharmacokinetics | Lactones - blood | Lactones - pharmacokinetics | Lactones - administration & dosage | Pyrroles - administration & dosage | Hydroxamic Acids - administration & dosage | Adult | Female | Antineoplastic Agents - pharmacokinetics | Proteasome Inhibitors - blood | Proteasome Inhibitors - pharmacokinetics | Carcinoma - drug therapy | Melanoma - metabolism | Hydroxamic Acids - blood | Proteasome Inhibitors - administration & dosage | Carcinoma, Non-Small-Cell Lung - metabolism | Pyrroles - blood | Hydroxamic Acids - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Melanoma - drug therapy | Antineoplastic Agents - blood | Cell Line, Tumor | Aged | Cell Proliferation - drug effects | Carcinoma - metabolism | Carcinoma, Non-Small-Cell Lung - drug therapy | Drug Combinations | Studies | Clinical trials | Pharmacology | Inhibitor drugs | Cancer therapies | Index Medicus
Journal Article
Journal Article
Clinical Pharmacokinetics, ISSN 0312-5963, 2019, Volume 58, Issue 8, pp. 1091 - 1100
IntroductionVenetoclax is a selective Bcell lymphoma-2 inhibitor. It is approved for treatment of chronic lymphocytic leukemia and is being investigated for... 
EFFICACY | SAFETY | CHRONIC LYMPHOCYTIC-LEUKEMIA | MALIGNANCIES | PHARMACOLOGY & PHARMACY | DYSFUNCTION | BORTEZOMIB | PHASE-I
Journal Article